Biohit Oyj (HEL:BIOBV)

Market Cap	33.59M -23.2%
Revenue (ttm)	15.73M +10.1%
Net Income	2.74M +6.6%
EPS	0.18 +6.3%
Shares Out	15.20M
PE Ratio	12.28
Forward PE	14.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,795
Average Volume	7,468
Open	2.270
Previous Close	2.210
Day's Range	2.240 - 2.320
52-Week Range	2.200 - 3.780
Beta	0.50
RSI	26.21
Earnings Date	Mar 18, 2026

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 46
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2025, Biohit Oyj's revenue was 15.73 million, an increase of 10.14% compared to the previous year's 14.28 million. Earnings were 2.74 million, an increase of 6.62%.